Daratumumab is indicated in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||02/06/2020|
|Rapid review completed||17/07/2020|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of daratumumab compared with the current standard of care.|